Abstract.
We evaluated a 1-year course of a newly developed immunosuppressant, mizoribine (at a dosage of 3 mg/kg body weight per day), in nine children with steroid-dependent nephrotic syndrome. Steroid treatment could be discontinued in two patients and the maintenance dosage of steroid could be reduced to less than half of that given before mizoribine therapy in a third. There were no beneficial effects in the remaining six patients. No adverse effects of mizoribine were observed during the course of therapy.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received September 20, 1996; received in revised form and accepted April 24, 1997
Rights and permissions
About this article
Cite this article
Hamasaki, T., Mori, M., Kinoshita, Y. et al. Mizoribine in steroid-dependent nephrotic syndrome of childhood. Pediatr Nephrol 11, 625–627 (1997). https://doi.org/10.1007/s004670050351
Issue Date:
DOI: https://doi.org/10.1007/s004670050351